| 2.14 0.01 (0.47%) | 10-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.74 | 1-year : | 3.2 |
| Resists | First : | 2.34 | Second : | 2.74 |
| Pivot price | 2.07 |
|||
| Supports | First : | 1.9 | Second : | 1.62 |
| MAs | MA(5) : | 2.14  |
MA(20) : | 2 |
| MA(100) : | 1.78 |
MA(250) : | 1.32 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 60 |
D(3) : | 62.7 |
| RSI | RSI(14): 56.6 |
|||
| 52-week | High : | 2.59 | Low : | 0.62 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ TLSA ] has closed below upper band by 33.6%. Bollinger Bands are 29.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.17 - 2.18 | 2.18 - 2.19 |
| Low: | 1.99 - 1.99 | 1.99 - 2 |
| Close: | 2.12 - 2.14 | 2.14 - 2.15 |
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.
Fri, 03 Oct 2025
Tiziana Life Sciences Reports Interim Results and Expands U.S. Presence - TipRanks
Tue, 30 Sep 2025
Tiziana Life Sciences to showcase drug candidate at Saudi innovation forum - Proactive financial news
Tue, 30 Sep 2025
Global Biotech Innovation Showcase: Tiziana Life Sciences Joins Elite Companies at Saudi LSIF 2025 - Stock Titan
Fri, 26 Sep 2025
Tiziana Life Sciences (NASDAQ:TLSA) Stock Price Down 0.5% - Should You Sell? - MarketBeat
Wed, 24 Sep 2025
First-Ever Intranasal Anti-CD3 Treatment: Tiziana Life Sciences Reveals MS Trial Design at Major Congress - Stock Titan
Tue, 23 Sep 2025
Tiziana Life Sciences Ltd (TLSA) Secures U.S. DoD Grant to Advance Intranasal Foralumab for Spinal Cord Injury - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 119 (M) |
| Shares Float | 71 (M) |
| Held by Insiders | 40.3 (%) |
| Held by Institutions | 3.8 (%) |
| Shares Short | 1,280 (K) |
| Shares Short P.Month | 792 (K) |
| EPS | -0.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.07 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -83.8 % |
| Return on Equity (ttm) | -232.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.16 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -17.84 |
| PEG Ratio | 0 |
| Price to Book value | 26.75 |
| Price to Sales | 0 |
| Price to Cash Flow | -29.06 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|